See more : Laredo Oil, Inc. (LRDC) Income Statement Analysis – Financial Results
Complete financial analysis of Puma Biotechnology, Inc. (PBYI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puma Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bigbloc Construction Limited (BIGBLOC.BO) Income Statement Analysis – Financial Results
- Zhongshen Jianye Hldg Ltd (2503.HK) Income Statement Analysis – Financial Results
- Acacia Pharma Group plc (ACPH.BR) Income Statement Analysis – Financial Results
- Terminus Energy, Inc. (TMGY) Income Statement Analysis – Financial Results
- Narrowstep Inc. (NRWS) Income Statement Analysis – Financial Results
Puma Biotechnology, Inc. (PBYI)
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.64M | 228.00M | 253.20M | 225.10M | 272.30M | 251.00M | 27.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 55.10M | 63.70M | 39.40M | 36.80M | 34.60M | 5.60M | 1.15M | 776.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.96M | 172.90M | 189.50M | 185.70M | 235.50M | 216.40M | 22.10M | -1.15M | -776.00K | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.40% | 75.83% | 74.84% | 82.50% | 86.49% | 86.22% | 79.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.38M | 52.20M | 71.90M | 97.70M | 132.90M | 164.90M | 207.80M | 222.80M | 208.50M | 122.90M | 45.05M | 49.60M | 826.37K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.43M | 89.98M | 116.29M | 118.49M | 140.51M | 146.19M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 881.00K | 22.00K | 6.00K | -88.00K | 1.19M | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.31M | 90.00M | 116.30M | 118.40M | 141.70M | 146.20M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 9.32M | 15.98K | 16.84K | 14.08K | 0.00 |
| Other Expenses | 625.00K | -28.00K | 300.00K | 400.00K | 200.00K | -9.70M | -100.00K | -400.00K | 25.00K | -14.00K | 2.00K | 293.00K | 10.70K | 0.00 | 0.00 | 0.00 | -15.09M |
| Operating Expenses | 140.32M | 142.20M | 188.20M | 216.10M | 274.60M | 311.10M | 314.50M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Cost & Expenses | 203.00M | 197.30M | 251.90M | 255.50M | 311.40M | 345.70M | 320.10M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Interest Income | 2.61M | 800.00K | 100.00K | 500.00K | 2.80M | 1.80M | 1.20M | 1.00M | 1.00M | 300.00K | 172.00K | 100.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.33M | 11.50M | 12.80M | 14.10M | 15.00M | 11.00M | 700.00K | 958.00K | 971.00K | 324.00K | 172.00K | 98.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.52M | 8.92M | 10.60M | 7.20M | 4.80M | 7.38M | 2.81M | 1.15M | 776.00K | 627.00K | 423.00K | 265.00K | 10.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 47.52M | 20.97M | -5.40M | -38.54M | -55.72M | -95.21M | -288.42M | -275.45M | -239.50M | -141.65M | -54.41M | -74.09M | -10.22M | -15.98K | -16.84K | -14.08K | -15.09M |
| EBITDA Ratio | 20.17% | 13.82% | 0.67% | -13.11% | -13.26% | -40.88% | -1,051.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,580.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 32.64M | 23.70M | -8.90M | -30.40M | -39.10M | -94.70M | -292.40M | -276.60M | -240.30M | -142.30M | -54.83M | -74.40M | -10.16M | -15.98K | -16.84K | -14.08K | -15.09M |
| Operating Income Ratio | 13.85% | 10.39% | -3.51% | -13.51% | -14.36% | -37.73% | -1,055.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,613.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.97M | -23.26M | -30.09M | -29.39M | 53.00K | -18.92M | 435.00K | 585.00K | 996.00K | 310.00K | 174.00K | 98.00K | -76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 22.67M | 500.00K | -28.80M | -59.80M | -75.60M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Income Before Tax Ratio | 9.62% | 0.22% | -11.37% | -26.57% | -27.76% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 500.00K | 300.00K | 200.00K | 7.12M | -7.92M | -2.21M | -2.15M | -1.75M | -941.00K | -172.00K | -267.00K | 76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 21.59M | 912.00K | -29.10M | -60.00M | -82.72M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Net Income Ratio | 9.16% | 0.40% | -11.49% | -26.65% | -30.38% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| EPS Diluted | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| Weighted Avg Shares Out | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
| Weighted Avg Shares Out (Dil) | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Clothing brands failing to eradicate forced labor risk in supply chains, research finds
Many of the world's major fashion brands are failing to combat forced labor in their supply chains, according to a new report.
3 Strong Buy Stocks Under $5: January 2024
Penny stocks are generally defined as stocks that trade for less than $5 per share. Low-priced stocks appeal to investors who can wait for these stock prices to appreciate.
4 Best Breakout Stocks to Buy for Superlative Returns
Universal Technical Institute (UTI), Puma Biotechnology (PBYI), Nomura (NMR) and Navigator Holdings (NVGS) have been selected as the breakout stocks for today.
PBYI or VRTX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
Puma Biotech (PBYI) Is Attractively Priced Despite Fast-paced Momentum
Puma Biotech (PBYI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Puma Biotech (PBYI) Stock Jumps 10.0%: Will It Continue to Soar?
Puma Biotech (PBYI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.
PBYI vs. VRTX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum...
Source: https://incomestatements.info
Category: Stock Reports